In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
|Articles|January 4, 2022
Israel Reports First Case of ‘Flurona’
Author(s)John Parkinson
A pregnant woman is reported to be the country’s first person to be infected simultaneously with COVID-19 and influenza.
Advertisement
A woman who was pregnant was reported to be the first case in Israel of a person who became simultaneously infected with both COVID-19 and influenza. This phenomenon is colloquially being referred to as the “flurona,” or “twindemic.”
According to one
Public health officials have been openly concerned about people contracting both going back to 2020. As such, clinicians and officials have been stressing the importance of vaccinations for both. People are able to get both vaccines at the same time with one in each arm.
Contagion recently released an e-book discussing this confounding condition. To learn more about the convergence of the 2 viruses, check out the recently published
Advertisement
Related to this article
FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
The latest CDC numbers show a 6.2% increase of measles cases from week-to-week. Last week there was a 5.4% increase in cases showing a continuing steady increase dictated by ongoing outbreaks across the US.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
IDSA/ESCMID panel member Henry Chambers, MD, explains why the new S aureus bacteremia guidance replaces the complicated vs uncomplicated label with risk stratification, and how the statements are akin to the stages of cancer in guiding treatment decisions associated with this bacteremia.
Advertisement
Advertisement
Trending on Contagion Live
1
Clinical Considerations for Measles: Presentation, Treatment, and Hospitalization
2
FAQ: Rising Rabies Exposure Calls PEP Decisions Back in Focus
3
Recent Guideline Updates in the Management of Urinary Tract Infections
4
Measles Update: October 2, 2026
5